Neurology News

An independent data monitoring committee has ruled that a phase 3 clinical trial investigating vidofludimus calcium for relapsing MS may continue as originally planned, according to the therapeutic’s manufacturer.

Treatment with diroximel fumarate was linked to lower rates of severe infection compared with anti-CD20 monoclonal antibodies for adults of all ages with MS, according to a poster presented at ECTRIMS.

Results from a clinical trial examining intracranial stimulation using a novel device in those with mild Alzheimer’s disease showed that treatment led to improvements in memory, cognitive function and blood flow.

Necessary changes within the health care system will only arise when workers are allowed more time and space personally and professionally, with ChatGPT the method by which this transformation can occur, according to Robert Pearl, MD.

Oral semaglutide demonstrated an approximately 14% reduction in major adverse CV events compared with standard care along in patients with diabetes, CVD and/or kidney disease, according to the top-line results of the phase 3 SOUL trial.

The new guideline on primary prevention of stroke from the American Heart Association and American Stroke Association calls for more screening of risk factors such as high BP, high cholesterol and high blood glucose.

Women with breast cancer who began an aerobic exercise program at the start of chemotherapy self-reported improved cognitive function and quality of life, according to results of a randomized trial.

Health Canada has approved Daybue to treat Rett syndrome in patients aged 2 years and older, according to manufacturer Acadia Pharmaceuticals.

The FDA has approved a supplemental new drug application for a once-daily, extended-release therapeutic to treat cataplexy or excessive daytime sleepiness in patients with narcolepsy aged 7 years and older, according to the manufacturer.

Topline data from a phase 2 clinical trial of an investigational gene therapy for Parkinson’s disease showed that a higher dose of the medication significantly improved disease-specific and quality of life measures by week 26.